Probiotic composition for treating rheumatoid arthritis and application thereof

Abstract

The invention relates to a probiotic composition for treating rheumatoid arthritis and application thereof, and relates to the technical field of probiotic compositions.The probiotic composition for treating rheumatoid arthritis is prepared from, by weight, 10-40 parts of lactobacillus johnsonii LBJ 456, 10-30 parts of lactobacillus helveticus HH-LPH17 and 10-30 parts of lactobacillus acidophilus HH-LA26. The bifidobacterium longum subsp. Longum HH-BL18, the bifidobacterium bifidum HH-BB27 and the bifidobacterium longum subsp. Infantis HH-BI27 are prepared from the following raw materials in parts by weight: 10 to 40 parts of bifidobacterium longum subsp. Probiotic strains with specific effects are screened out, the combination proportion of the probiotic strains is optimized, the probiotic composition for treating rheumatoid arthritis is prepared, and a novel safe and effective adjuvant therapy method is provided for treatment of RA.

Description

Technical Field

[0001] This invention relates to the field of probiotic composition technology, and more particularly to a probiotic composition for treating rheumatoid arthritis and its application. Background Technology

[0002] Rheumatoid arthritis (RA), a systemic autoimmune disease characterized by erosive joint inflammation, still heavily relies on pharmacological interventions for its clinical treatment. Current mainstream treatments include nonsteroidal anti-inflammatory drugs (NSAIDs), small-molecule targeted therapies, and glucocorticoids. However, significant unmet clinical needs remain regarding long-term efficacy maintenance, medication safety management, and individualized treatment responses. Notably, existing treatments are unlikely to substantially reverse disease progression, and long-term use may be accompanied by increased risk of infection and metabolic disorders, highlighting the urgent need for developing novel treatment strategies.

[0003] In recent years, research on the link between gut microbiota and the pathogenesis of rheumatoid arthritis (RA) has opened up new avenues for disease intervention. The gut microbiota in the human gut constitutes a dynamically balanced micro-ecosystem, forming a precise regulatory network with the host immune system through pattern recognition receptors. It has shown potential application value in the intervention and treatment of RA, but existing research still has limitations such as unsatisfactory treatment effects. Therefore, developing a probiotic composition specifically for the treatment of rheumatoid arthritis with excellent therapeutic effects is of significant practical importance. Summary of the Invention

[0004] To address the above problems, the present invention provides a probiotic composition for treating rheumatoid arthritis and its application.

[0005] In a first aspect, the present invention provides a probiotic composition for treating rheumatoid arthritis, wherein, by weight, the probiotic composition for treating rheumatoid arthritis comprises the following components:

[0006] Lactobacillus johnsonii LBJ 456 10-40 samples, Lactobacillus helveticus HH-LPH17 10-30 samples, Lactobacillus acidophilus HH-LA26 10-30 samples, Bifidobacterium longum subsp. longum HH-BL18 10-40 samples, Bifidobacterium bifidum HH-BB27 10-40 samples, and Bifidobacterium longum subsp. infantum HH-BI27 10-30 samples.

[0007] Furthermore, 20 samples of Lactobacillus johnsonii LBJ 456, 20 samples of Lactobacillus helveticus HH-LPH17, 10 samples of Lactobacillus acidophilus HH-LA26, 20 samples of Bifidobacterium longum subsp. longum HH-BL18, 10 samples of Bifidobacterium bifidum HH-BB27, and 20 samples of Bifidobacterium longum subsp. infantum HH-BI27 were collected.

[0008] Secondly, based on the same inventive concept, the present invention provides the use of the probiotic composition for treating rheumatoid arthritis as described in any one of the first aspects in the preparation of products for treating rheumatoid arthritis.

[0009] The technical solutions provided in the embodiments of the present invention have at least the following advantages compared with the prior art:

[0010] This invention provides a probiotic composition for treating rheumatoid arthritis and its application. The invention screens probiotic strains with specific effects and optimizes their combination ratio to prepare a probiotic composition for treating rheumatoid arthritis, providing a new, safe, and effective adjunctive treatment method for RA. Detailed Implementation

[0011] To make the objectives, technical solutions, and advantages of the embodiments of the present invention clearer, the technical solutions in the embodiments of the present invention will be clearly and completely described below. Obviously, the described embodiments are only some, not all, of the embodiments of the present invention. Based on the embodiments of the present invention, all other embodiments obtained by those skilled in the art without creative effort are within the scope of protection of the present invention.

[0012] Unless otherwise specified, various raw materials, reagents, instruments and equipment used in the present invention can be purchased from the market or prepared by existing methods.

[0013] The present invention will be further illustrated below with reference to specific embodiments. It should be understood that these embodiments are for illustrative purposes only and are not intended to limit the scope of the invention. Experimental methods in the following embodiments, unless otherwise specified, are generally performed according to national standards. If no corresponding national standard exists, then generally accepted international standards, conventional conditions, or conditions recommended by the manufacturer are followed.

[0014] The main strains involved in this invention are as follows:

[0015] The Bifidobacterium bifidum HH-BB27 was deposited at the China Center for Type Culture Collection on July 5, 2023, at Wuhan University, Wuhan, China, with accession number CCTCC NO:M 20231198.

[0016] The specific preservation information of Lactobacillus johnsonii LBJ 456 is as follows: it was deposited on December 5, 2019 at the China Center for Type Culture Collection, located at Wuhan University, Wuhan, China, with accession number CCTCCNO:M 20191013.

[0017] The specific preservation information of the Lactobacillus helveticus HH-LPH17 is as follows: it was deposited at the China Center for Type Culture Collection (CCTCC) on June 15, 2021, at Wuhan University, Wuhan, China, with accession number CCTCC NO: M 2021725.

[0018] The specific preservation information of the Lactobacillus acidophilus HH-LA26 is as follows: it was deposited at the China Center for Type Culture Collection on March 24, 2022, at Wuhan University, Wuhan, China, with accession number CCTCC NO:M 2022305;

[0019] The specific preservation information of the Bifidobacterium longum subspecies HH-BL18 is as follows: it was deposited at the China Center for Type Culture Collection on March 24, 2022, at Wuhan University, Wuhan, China, with accession number CCTCC NO:M 2022306.

[0020] The specific preservation information for the *Bifidobacterium longum* subspecies *HH-BI27* is as follows: it was deposited on July 5, 2023, at the China Center for Type Culture Collection (CCTCC), located at Wuhan University, Wuhan, China, with accession number CCTCC NO: M20231197.

[0021] Example 1

[0022] This example provides a probiotic composition for treating rheumatoid arthritis, comprising the following components in parts by weight:

[0023] 20 samples of Lactobacillus johnsonii LBJ 456, 20 samples of Lactobacillus helveticus HH-LPH17, 10 samples of Lactobacillus acidophilus HH-LA26, 20 samples of Bifidobacterium longum subsp. longum HH-BL18, 10 samples of Bifidobacterium bifidum HH-BB27, and 20 samples of Bifidobacterium longum subsp. infantum HH-BI27.

[0024] The preparation method of the above-mentioned probiotic composition for treating rheumatoid arthritis includes: mixing the various probiotics to form a compound bacterial powder.

[0025] Example 2

[0026] This example provides a probiotic composition for treating rheumatoid arthritis, comprising the following components in parts by weight:

[0027] 10 samples of Lactobacillus johnsonii LBJ 456, 10 samples of Lactobacillus helveticus HH-LPH17, 10 samples of Lactobacillus acidophilus HH-LA26, 10 samples of Bifidobacterium longum subsp. longum HH-BL18, 10 samples of Bifidobacterium bifidum HH-BB27, and 10 samples of Bifidobacterium longum subsp. infantum HH-BI27.

[0028] The preparation method of the above-mentioned probiotic composition for treating rheumatoid arthritis includes: mixing the various probiotics to form a compound bacterial powder.

[0029] Example 3

[0030] This example provides a probiotic composition for treating rheumatoid arthritis, comprising the following components in parts by weight:

[0031] 40 samples of Lactobacillus johnsonii LBJ 456, 30 samples of Lactobacillus helveticus HH-LPH17, 30 samples of Lactobacillus acidophilus HH-LA26, 40 samples of Bifidobacterium longum subsp. longum HH-BL18, 40 samples of Bifidobacterium bifidum HH-BB27, and 30 samples of Bifidobacterium longum subsp. infantum HH-BI27.

[0032] The preparation method of the above-mentioned probiotic composition for treating rheumatoid arthritis includes: mixing the various probiotics to form a compound bacterial powder.

[0033] Comparative Example 1

[0034] This example provides a probiotic for treating rheumatoid arthritis, which differs from Example 1 only in that it includes only Lactobacillus johnsonii LBJ 456 as in Example 1; all other steps and parameters are the same.

[0035] Comparative Example 2

[0036] This example provides a probiotic for treating rheumatoid arthritis, which differs from Example 1 only in that it includes only Lactobacillus helveticus HH-LPH17 as in Example 1; all other steps and parameters are the same.

[0037] Comparative Example 3

[0038] This example provides a probiotic for treating rheumatoid arthritis, which differs from Example 1 only in that it includes only Lactobacillus acidophilus HH-LA26 as in Example 1; all other steps and parameters are the same.

[0039] Comparative Example 4

[0040] This example provides a probiotic for treating rheumatoid arthritis, which differs from Example 1 only in that it includes only Bifidobacterium longum subsp. longum HH-BL18, Bifidobacterium bifidum HH-BB27 and Bifidobacterium longum subsp. infantum HH-BI27 from Example 1; all other steps and parameters are the same.

[0041] Test Case

[0042] This example aims to examine the therapeutic effect of the probiotic compositions for treating rheumatoid arthritis obtained in Example 1 and Comparative Examples 1-4 on rheumatoid arthritis.

[0043] Test Method: Several SD rats were used to establish a rheumatoid arthritis model. 10 mg of type II collagen was mixed with 0.05 mmol / L acetic acid solution at 4°C and diluted to 5 mL. Then, 5 mL of incomplete Freund's adjuvant was added to obtain a mixed emulsion. 0.1 mL of this solution was subcutaneously injected into the tail base of each group of rats for primary immunization. A second injection was given 7 days later to establish the rheumatoid arthritis model. Successful model establishment was indicated by redness and swelling of the limbs and tail. Rats with successful model establishment were randomly assigned to groups for testing. The test results are shown in Tables 1 and 2. In Tables 1 and 2, the Pro-L group represents the low-dose group, with a dosage of 5 × 10⁻⁶ mg / L. 8 CFU / animal; Pro-H group indicates the high-dose group, with a dosage of 5 × 10⁻⁶. 9 CFU / each.

[0044] Table 1

[0045]

[0046]

[0047] Table 2

[0048]

[0049] Table 1 shows that after modeling, the rats in the model group exhibited obvious redness and swelling of the limbs and tail, and the levels of factors such as IL-1β and IL-6 increased significantly, proving that the modeling was successful. Compared with the model group, the inflammatory factor indicators in each probiotic group showed a significant decreasing trend. Although they did not reach the levels of the control group, they were significantly different from those in the model group.

[0050] Table 2 shows that after the model was established, the levels of malondialdehyde, superoxide dismutase, and catalase in the rat blood all changed significantly. After intervention with different groups of probiotics, the malondialdehyde content decreased significantly. Although the levels of superoxide dismutase and catalase did not reach the control group, they were significantly higher than those in the model group.

[0051] Various embodiments of the present invention may exist in the form of a range; it should be understood that the description in the form of a range is merely for convenience and brevity and should not be construed as a hard limitation on the scope of the invention; therefore, it should be considered that the range description has specifically disclosed all possible subranges and single numerical values ​​within that range. For example, it should be considered that the range description from 1 to 6 has specifically disclosed subranges such as from 1 to 3, from 1 to 4, from 1 to 5, from 2 to 4, from 2 to 6, from 3 to 6, etc., and single numbers within the range, such as 1, 2, 3, 4, 5, and 6, regardless of the range. Furthermore, whenever a numerical range is referred to herein, it means including any referenced number (fraction or integer) within the range referred to.

[0052] The above description is merely a specific embodiment of the present invention, enabling those skilled in the art to understand or implement the invention. Various modifications to these embodiments will be readily apparent to those skilled in the art, and the general principles defined herein may be implemented in other embodiments without departing from the spirit or scope of the invention. Therefore, the present invention is not to be limited to the embodiments shown herein, but is to be accorded the widest scope consistent with the principles and novel features claimed herein.

Claims

1. A probiotic composition for treating rheumatoid arthritis, characterized in that, The probiotic composition for treating rheumatoid arthritis comprises the following components in parts by weight: Lactobacillus johnsonii LBJ 456 10-40 samples, Lactobacillus helveticus HH-LPH17 10-30 samples, Lactobacillus acidophilus HH-LA26 10-30 samples, Bifidobacterium longum subsp. longum HH-BL18 10-40 samples, Bifidobacterium bifidum HH-BB27 10-40 samples, and Bifidobacterium longum subsp. infantum HH-BI27 10-30 samples.

2. The probiotic composition for treating rheumatoid arthritis according to claim 1, characterized in that, 20 samples of Lactobacillus johnsonii LBJ 456, 20 samples of Lactobacillus helveticus HH-LPH17, 10 samples of Lactobacillus acidophilus HH-LA26, 20 samples of Bifidobacterium longum subsp. longum HH-BL18, 10 samples of Bifidobacterium bifidum HH-BB27, and 20 samples of Bifidobacterium longum subsp. infantum HH-BI27.

3. The use of the probiotic composition for treating rheumatoid arthritis according to any one of claims 1 to 2 in the preparation of products for treating rheumatoid arthritis.

Images